Does Guardant Health (GH) Have Long-Runway for Growth?

In its first-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Guardant Health, Inc. (NASDAQ:GH). Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution that specializes successful a liquid biopsy trial to observe crab from humor samples. On May 1, 2026, Guardant Health, Inc. (NASDAQ:GH) closed astatine $87.60 per share. One-month instrumentality of Guardant Health, Inc. (NASDAQ:GH) was -2.30%, and its shares gained 98.86% implicit the past 52 weeks. Guardant Health, Inc. (NASDAQ:GH) has a marketplace capitalization of $11.49 billion.

Baron Health Care Fund stated the pursuing regarding Guardant Health, Inc. (NASDAQ:GH) successful its Q1 2026 capitalist letter:

"We bought shares of Guardant Health, Inc. (NASDAQ:GH), a diagnostics institution which offers a portfolio of humor and tissue-based tests that are utilized for therapy enactment for patients with precocious signifier cancer, monitoring for recurrence successful early-stage crab patients, and screening for early-stage crab successful asymptomatic patients. Guardant’s flagship product, Guardant360, is the marketplace starring liquid biopsy trial utilized to assistance pass physicians which therapy whitethorn beryllium effectual for precocious signifier crab patients with coagulated tumors without the request to get archival insubstantial oregon taxable the diligent to an invasive biopsy. Therapy enactment is simply a $10 cardinal marketplace opportunity, according to absorption estimates. Guardant Reveal provides minimal residual illness detection, recurrence monitoring and late-stage therapy monitoring, which correspond a $20 cardinal marketplace opportunity, according to absorption estimates. This year, the institution volition motorboat Guardant Reveal Ultra, a tissue-informed assay. Guardant is successful the aboriginal innings of the motorboat of Shield, a humor trial for colorectal crab screening successful adults property 45 and older who are astatine mean hazard for the disease. Based connected our estimates, colorectal screening is an $18 cardinal yearly marketplace opportunity, and adoption of Shield has exceeded Wall Street expert expectations to date. Management plans to summation the Shield income unit from 300 to 600 and partnered with Quest Diagnostics to supply expanded entree to physicians and patients. In the future, the institution expects to grow into lung crab screening and multi-cancer detection with the Shield platform. Guardant’s concern has accelerated the past fewer years, and successful 2025 the institution generated 33% gross growth. Excluding Shield, Guardant generated affirmative escaped currency travel successful Q3 and Q4 2025, and absorption is targeting escaped currency travel breakeven successful Q4 2027. With currency astatine twelvemonth extremity 2025 of $1.3 billion, Guardant has the equilibrium expanse to execute its maturation plans. Management is targeting 27% to 30% gross maturation successful 2026 and we deliberation the institution has a agelong runway for aboriginal maturation beyond 2026 with accidental for important escaped currency travel procreation successful the retired years."